Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by PET.
about
A philosophy for CNS radiotracer designRadionuclide labeling and evaluation of candidate radioligands for PET imaging of histone deacetylase in the brainImage-guided synthesis reveals potent blood-brain barrier permeable histone deacetylase inhibitors.Intractable itch relieved by 4-phenylbutyrate therapy in patients with progressive familial intrahepatic cholestasis type 1Design, synthesis, and evaluation of hydroxamic acid-based molecular probes for in vivo imaging of histone deacetylase (HDAC) in brain.Kinetic Analysis and Quantification of [¹¹C]Martinostat for in Vivo HDAC Imaging of the Brain.Attenuation of ER stress prevents post-infarction-induced cardiac rupture and remodeling by modulating both cardiac apoptosis and fibrosis.The histone deacetylase inhibitor, sodium butyrate, exhibits neuroprotective effects for ischemic stroke in middle-aged female rats.The role of butyrate, a histone deacetylase inhibitor in diabetes mellitus: experimental evidence for therapeutic intervention.Anti-diabetic Effects of Clostridium butyricum CGMCC0313.1 through Promoting the Growth of Gut Butyrate-producing Bacteria in Type 2 Diabetic Mice.Molecular Imaging of Hydrolytic Enzymes Using PET and SPECT.Gut-Brain Axis in Regulation of Blood Pressure.Inhibition of HDAC3 prevents diabetic cardiomyopathy in OVE26 mice via epigenetic regulation of DUSP5-ERK1/2 pathway.
P2860
Q26853140-62A7E44F-12B0-4451-A31C-B2B005547C9BQ33556502-7DA7849F-844C-45BE-883B-049FAC48E773Q33918201-1AA09C71-626F-41D6-B466-6B686207A40FQ33929416-9C1C891A-9751-49B9-AEC5-4B4EC8AF909CQ34395031-7BBF71B3-B0AB-4E3B-9828-6E7FCFA8DDB9Q34467002-32980146-303D-4728-B4D5-856C1051FF5CQ36384602-B2FEEB1B-2A3E-4494-8ED5-3F9BB7ECB09AQ37460436-88572547-05E9-4161-B4E4-3FBC96EAB074Q38537774-237D60B5-DAD2-4AB8-901D-485E60E04307Q41203575-1573572A-0CCB-4D47-BC0A-D206AAF50F50Q41862863-5D9E5BD7-C8FF-4ED2-A193-1A49CA661279Q47136595-D0EF1327-56AF-4140-AB5C-E4DC5252CA5BQ50630504-726C146E-A90C-4069-8DFD-CFEE2479A6DF
P2860
Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by PET.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Whole-body pharmacokinetics of ...... bon-11 labeled analogs by PET.
@ast
Whole-body pharmacokinetics of ...... bon-11 labeled analogs by PET.
@en
Whole-body pharmacokinetics of ...... bon-11 labeled analogs by PET.
@nl
type
label
Whole-body pharmacokinetics of ...... bon-11 labeled analogs by PET.
@ast
Whole-body pharmacokinetics of ...... bon-11 labeled analogs by PET.
@en
Whole-body pharmacokinetics of ...... bon-11 labeled analogs by PET.
@nl
prefLabel
Whole-body pharmacokinetics of ...... bon-11 labeled analogs by PET.
@ast
Whole-body pharmacokinetics of ...... bon-11 labeled analogs by PET.
@en
Whole-body pharmacokinetics of ...... bon-11 labeled analogs by PET.
@nl
P2093
P2860
P1476
Whole-body pharmacokinetics of ...... rbon-11 labeled analogs by PET
@en
P2093
Alicia E Reid
Colleen Shea
Joanna S Fowler
Khaing Win
Lisa Muench
Nicola Otto
Nora D Volkow
Pauline Carter
Payton King
Sung Won Kim
P2860
P304
P356
10.1016/J.NUCMEDBIO.2013.06.007
P577
2013-07-29T00:00:00Z